Life sciences company Bio-Techne Corporation (NASDAQ: TECH) announced on Wednesday that its board of directors has approved a quarterly dividend of USD0.08 per share for Q3 2024.
This dividend is payable on 22 November 2024 to shareholders of record as of 11 November 2024.
The company said its board will continue to evaluate cash dividends on a quarterly basis.
Bio-Techne provides essential tools and reagents for research and clinical diagnostics, supporting drug discovery and accurate clinical testing. In fiscal 2024, the company reported USD1.2bn in net sales and employs approximately 3,100 people worldwide.
FDA extends Biohaven's PDUFA date for troriluzole NDA for spinocerebellar ataxia
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Clarivate adds Pathway Maps to OFF-X, boosting drug safety intelligence
GSK to acquire efimosfermin in USD2bn deal to expand hepatology pipeline
Hemogenyx Pharmaceuticals expands HG-CT-1 trial to include paediatric AML patients
Cumberland Pharmaceuticals partners Qureight for idiopathic pulmonary fibrosis treatment research
Hoth Therapeutics reports positive HT-KIT preclinical results
Solve M.E. announces Dr Akiko Iwasaki as first recipient of inaugural ME/CFS Catalyst Award
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
RemeGen reports positive phase 3 results for disitamab vedotin in advanced urothelial carcinoma
Lilly and Purdue University expand collaboration, announce investment
AstraZeneca's Imfinzi improves disease-free survival in early bladder cancer trial